A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy
Latest Information Update: 27 Jun 2025
At a glance
- Drugs Cetrelimab (Primary) ; Gemcitabine (Primary) ; Cisplatin; Gemcitabine
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms SunRISe-2
- Sponsors Janssen Research & Development; Janssen-Cilag
Most Recent Events
- 22 Jun 2025 Planned End Date changed from 26 Dec 2029 to 31 Dec 2028.
- 07 Nov 2024 According to the XOMA media release, Status changed from active, no longer recruiting to discontinued.
- 07 Nov 2024 According to the XOMA media release, being discontinued for not showing superiority to chemoradiation during a scheduled interim analysis.